---
title: "Liminatus Pharma jumps 52% after Nasdaq tier adjustment and compliance extension"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295829258.md"
description: "Liminatus Pharma (LIMN) surged 52% during regular trading after moving to Nasdaq Capital Market tier and securing a compliance extension."
datetime: "2026-08-13T17:22:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295829258.md)
  - [en](https://longbridge.com/en/news/295829258.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295829258.md)
generator: "portal-rs"
---

# Liminatus Pharma jumps 52% after Nasdaq tier adjustment and compliance extension

Liminatus Pharma(LIMN.US) 盘中快速拉升，当日涨超 52%，现报 0.1657 美元。

消息面上，该公司于 8 月 13 日将纳斯达克上市层级调整至资本市场 tier，股份将继续以 LIMN 代码交易。此外，纳斯达克已批准延长其重新满足最低股价要求的期限，截止日期为 2026 年 9 月 3 日。该医疗股在周四交易时段表现活跃，盘前一度飙升超 55%，成为当日 12 只异动医疗股之一。

### Related Stocks

- [LIMN.US](https://longbridge.com/en/quote/LIMN.US.md)

## Related News & Research

- [Liminatus Pharma discloses Ewon Comfortech initial beneficial ownership of 5.5 million shares](https://longbridge.com/en/news/291844263.md)
- [Liminatus Pharma annual meeting draws 48.31% of shares represented](https://longbridge.com/en/news/294876806.md)
- [Liminatus Pharma Q2 FY26 net loss widens to $1.41 million; operating loss widens 23% to $1.38 million](https://longbridge.com/en/news/295975537.md)
- [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**